Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Peripheral T-cell Lymphoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Anti-Inflammatory Agents

Anti-Infective Agents

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Prednisone

Vincristine

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Tubulin Modulators

Antimitotic Agents

Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.

Golidocitinib

CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.

CHOP Regimen

Keshu Zhou, Dr.

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).

Go-CHOP as the Frontline Therapy for PTCL

A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL)

Complete response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria

Objective response rate by Cycle 3 and Cycle 6 assessed by investigator per Lugano 2014 criteria.

Duration of response assessed by investigator per Lugano 2014 criteria

Henan Cancer Hospital

Professor

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Pemetrexed

Dose escalation part Golidocitinib in combination with sintilimab

Dose expansion cohort 1, Golidositinib plus Sintilimab following Sintilimab

Dose expansion cohort 2, Golidositinib plus Sintilimab following Sintilimab + chemotherapy

Sintilimab, 200mg, intravenous, every 3 weeks.

Sintilimab

Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles

platinum doublet chemotherapy

Jie Wang, MD,PhD

Jie Wang, MD, PhD

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)

Complete response (CR) or partial response (PR) per investigator assessment according to RECIST 1.1

Time from first administration of study drug to first documented disease progression or death per investigator assessment according to RECIST 1.1

time from first administration of study drug to death

Frequency an severity of AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Dizal Pharmaceuticals

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Chief Physician

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Go-CHOP as the Frontline Therapy for PTCL	NCT05963347	Peripheral T Ce...	Golidocitinib CHOP Regimen	18 Years -	Henan Cancer Hospital
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)	NCT06198907	Non-Small-Cell ...	Golidocitinib Sintilimab platinum double...	18 Years - 75 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Spots Global Cancer Trial Database for golidocitinib